Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05755204 · ClinicalTrials.gov registry record

A Pharmacist-run PrEP Program for Women

A clinical trial, sponsored by Orlando Immunology Center.

Terminated
Registry status
2
Enrollment target

NCT05755204: Clinical Trial study, sponsored by Orlando Immunology Center.

NCT05755204 is a clinical trial that was terminated before completion, run by Orlando Immunology Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05755204 was terminated before completion, sponsored by Orlando Immunology Center.

TERMINATED
Registry status
2 participants
Enrollment target

Study Summary

The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also include reasons for lack of retention in PrEP care)

Primary Outcome

proportion of women who initiate LA-CAB vs. TDF/FTC for PrEP

Interventions

  • DRUG TDF/FTC
  • DRUG LA-CAB

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2023-06-21
Est. Completion 2024-10-15
Orlando Immunology Center

3 total trials

Why NCT05755204 stopped before completion

NCT05755204 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which TDF/FTC is the first listed.

NCT05755204 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05755204 about?

NCT05755204 is a clinical study titled "A Pharmacist-run PrEP Program for Women". The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also i...

What is the current status of trial NCT05755204?

This trial is currently terminated. The enrollment target is 2 participants. The study started on 2023-06-21. Estimated completion is 2024-10-15.

What interventions are being tested in trial NCT05755204?

The interventions under investigation include: TDF/FTC (DRUG), LA-CAB (DRUG).

Who is sponsoring clinical trial NCT05755204?

This trial is sponsored by Orlando Immunology Center, which has 3 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05326451 · started 2023-06-21 · NA

    Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease

  • NCT05351801 · started 2023-06-21 · Phase 2

    Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain

  • NCT05620342 · started 2023-06-21 · Early Phase 1

    Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

  • NCT05752500 · started 2023-06-21 · NA

    Optimization of a Behavioral Intervention to Increase Physical Activity in Older Adults Living With HIV

Source: ClinicalTrials.gov NCT05755204, the US trial registry maintained by the National Library of Medicine. NCT05755204 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.